Tirzepatide vs retatrutide: dual and triple agonists, side by side

"Tirzepatide vs retatrutide" is one of the most common searches in this category, and almost every page that answers it does so by lining up weight-loss percentages from different trials — which is not a comparison, it's a juxtaposition. This article compares the two compounds on the things that can be compared honestly.

The short version

Chemistry

Both molecules start from the sequence of GIP, the 42-residue gut hormone, shortened to 39 residues and modified so that the peptide also engages the GLP-1 receptor. Both carry a lipid side chain attached via a linker to a lysine residue — this binds albumin in circulation and is what gives each compound a half-life measured in days rather than minutes.

Retatrutide goes one step further: additional substitutions give it activity at the glucagon receptor as well. In cell assays the three activities are deliberately unbalanced — the compound is more potent at some receptors than others — which is a design choice discussed in the discovery paper rather than an accident.

The practical consequence for an analytical lab is small: the two compounds are close in mass and behave similarly on a reversed-phase HPLC column, so a certificate's observed mass is the field that distinguishes them, not the retention time. How to check that field.

Receptors

GIP and GLP-1 are the two incretin hormones. Both are released from the intestine after eating; both act on the pancreatic beta cell and on appetite circuits in the brainstem and hypothalamus. Tirzepatide's contribution to the field was demonstrating that a single peptide could engage both.

Glucagon is released by the pancreatic alpha cell and acts mainly on the liver, raising glucose output and increasing energy expenditure. Adding glucagon-receptor agonism to an incretin peptide is the idea behind the "triple agonist" class, of which retatrutide is the most advanced example.

What each combination does in a human being is precisely what the trial programmes exist to determine, and precisely what we don't summarise here.

Trial programmes and where to read them

Tirzepatide has a complete, published phase 3 programme: SURPASS-1 through SURPASS-6 in type 2 diabetes, SURMOUNT-1 through SURMOUNT-4 in obesity, and a growing set of follow-on studies. Headline papers appeared in the New England Journal of Medicine and The Lancet between 2021 and 2023.

Retatrutide has published phase 2 results — Jastreboff et al. (NEJM, 2023) in obesity and Rosenstock et al. (The Lancet, 2023) in type 2 diabetes — and a phase 3 programme with results emerging through 2025–26.

The two have not been compared against each other in a published randomised trial. Any page that presents a number for one beside a number for the other is comparing different populations, different durations, different dosing schedules and different years. That is not information you can act on, so we don't present it.

Regulatory status — the important difference

This is where the two diverge most sharply, and where a buyer of research material needs to be clear-eyed.

Tirzepatide is a licensed medicine. In the UK it is marketed by Lilly as Mounjaro, authorised by the MHRA for type 2 diabetes and for weight management, and available on prescription. Research-grade tirzepatide supplied by Biovanta is not Mounjaro: it is not a medicine, has not been through any regulator's release process, and is supplied purely for laboratory use. The existence of a licensed product changes nothing about the legal status of the research material — it may only be sold for research.

Retatrutide has no marketing authorisation anywhere. It cannot be prescribed. It is lawful to buy and hold for research.

Research supply — where they're the same

In everything that matters to a laboratory receiving a parcel, the two are handled identically:

• Manufactured in Switzerland, one facility, one process.
• Supplied as a solution in a pre-filled 40 mg pen with needles and swabs — why a pen rather than a vial.
• Stored and shipped at 2–8°C; do not freeze, keep in the carton.
• Manufacturer HPLC-MS certificate per batch, available before you order; batch figures on the testing page.
• Supplied for in-vitro laboratory research only.

The only supply-side difference is the price: Tirzepatide 40 mg is £160 and Retatrutide 40 mg is £200, which reflects the manufacturer's cost rather than any judgement about the compounds.